These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 25228355)

  • 1. Sclerostin declines during hemodialysis and appears in Dialysate.
    Bielesz BO; Hempfing T; Kieweg H; Marculescu R; Haas M; Cejka D
    Blood Purif; 2014; 38(1):30-6. PubMed ID: 25228355
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factors associated with serum soluble inhibitors of Wnt-β-catenin signaling (sclerostin and dickkopf-1) in patients undergoing peritoneal dialysis.
    Yamada S; Tsuruya K; Tokumoto M; Yoshida H; Ooboshi H; Kitazono T
    Nephrology (Carlton); 2015 Sep; 20(9):639-45. PubMed ID: 25974190
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship between serum sclerostin, bone metabolism markers, and bone mineral density in maintenance hemodialysis patients.
    Ishimura E; Okuno S; Ichii M; Norimine K; Yamakawa T; Shoji S; Nishizawa Y; Inaba M
    J Clin Endocrinol Metab; 2014 Nov; 99(11):4315-20. PubMed ID: 25093620
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sclerostin blood levels before and after kidney transplantation.
    Bonani M; Rodriguez D; Fehr T; Mohebbi N; Brockmann J; Blum M; Graf N; Frey D; Wüthrich RP
    Kidney Blood Press Res; 2014; 39(4):230-9. PubMed ID: 25118597
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clearance of Sclerostin, Osteocalcin, Fibroblast Growth Factor 23, and Osteoprotegerin by Dialysis.
    Carlson N; Mortensen OH; Axelsen M; Pedersen RS; Heaf JG
    Blood Purif; 2017; 44(2):122-128. PubMed ID: 28554171
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sclerostin serum levels correlate positively with bone mineral density and microarchitecture in haemodialysis patients.
    Cejka D; Jäger-Lansky A; Kieweg H; Weber M; Bieglmayer C; Haider DG; Diarra D; Patsch JM; Kainberger F; Bohle B; Haas M
    Nephrol Dial Transplant; 2012 Jan; 27(1):226-30. PubMed ID: 21613383
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum sclerostin: the missing link in the bone-vessel cross-talk in hemodialysis patients?
    Pelletier S; Confavreux CB; Haesebaert J; Guebre-Egziabher F; Bacchetta J; Carlier MC; Chardon L; Laville M; Chapurlat R; London GM; Lafage-Proust MH; Fouque D
    Osteoporos Int; 2015 Aug; 26(8):2165-74. PubMed ID: 25910747
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sclerostin quo vadis? - is this a useful long-term mortality parameter in prevalent hemodialysis patients?
    Nowak A; Artunc F; Serra AL; Pollock E; Krayenbühl PA; Müller C; Friedrich B
    Kidney Blood Press Res; 2015; 40(3):266-76. PubMed ID: 25997652
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sclerostin levels in uremic patients: a link between bone and vascular disease.
    Bruzzese A; Lacquaniti A; Cernaro V; Ricciardi CA; Loddo S; Romeo A; Montalto G; Costantino G; Torre F; Pettinato G; Salamone I; Aloisi C; Santoro D; Buemi M
    Ren Fail; 2016 Jun; 38(5):759-64. PubMed ID: 27001371
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intradialytic changes of serum magnesium and their relation to hypotensive episodes in hemodialysis patients on different dialysates.
    Elsharkawy MM; Youssef AM; Zayoon MY
    Hemodial Int; 2006 Oct; 10 Suppl 2():S16-23. PubMed ID: 17022745
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum sclerostin and adverse outcomes in nondialyzed chronic kidney disease patients.
    Kanbay M; Siriopol D; Saglam M; Kurt YG; Gok M; Cetinkaya H; Karaman M; Unal HU; Oguz Y; Sari S; Eyileten T; Goldsmith D; Vural A; Veisa G; Covic A; Yilmaz MI
    J Clin Endocrinol Metab; 2014 Oct; 99(10):E1854-61. PubMed ID: 25057883
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum sclerostin levels, arteriovenous fistula calcification and 2-years all-cause mortality in prevalent hemodialysis patients.
    Kirkpantur A; Balci M; Turkvatan A; Afsar B
    Nefrologia; 2016; 36(1):24-32. PubMed ID: 26546060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predialysis serum sodium level, dialysate sodium, and mortality in maintenance hemodialysis patients: the Dialysis Outcomes and Practice Patterns Study (DOPPS).
    Hecking M; Karaboyas A; Saran R; Sen A; Hörl WH; Pisoni RL; Robinson BM; Sunder-Plassmann G; Port FK
    Am J Kidney Dis; 2012 Feb; 59(2):238-48. PubMed ID: 21944663
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating sclerostin and Dickkopf-1 (DKK1) in predialysis chronic kidney disease (CKD): relationship with bone density and arterial stiffness.
    Thambiah S; Roplekar R; Manghat P; Fogelman I; Fraser WD; Goldsmith D; Hampson G
    Calcif Tissue Int; 2012 Jun; 90(6):473-80. PubMed ID: 22527202
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sclerostin: another bone-related protein related to all-cause mortality in haemodialysis?
    Viaene L; Behets GJ; Claes K; Meijers B; Blocki F; Brandenburg V; Evenepoel P; D'Haese PC
    Nephrol Dial Transplant; 2013 Dec; 28(12):3024-30. PubMed ID: 23605174
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of bone-derived biomarkers with vascular calcification in chronic hemodialysis patients.
    Lee YT; Ng HY; Chiu TT; Li LC; Pei SN; Kuo WH; Lee CT
    Clin Chim Acta; 2016 Jan; 452():38-43. PubMed ID: 26522655
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High levels of circulating sclerostin are associated with better cardiovascular survival in incident dialysis patients: results from the NECOSAD study.
    Drechsler C; Evenepoel P; Vervloet MG; Wanner C; Ketteler M; Marx N; Floege J; Dekker FW; Brandenburg VM;
    Nephrol Dial Transplant; 2015 Feb; 30(2):288-93. PubMed ID: 25248363
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum sclerostin levels associated with lumbar spine bone mineral density and bone turnover markers in patients with postmenopausal osteoporosis.
    Xu XJ; Shen L; Yang YP; Lu FR; Zhu R; Shuai B; Li CG; Wu MX
    Chin Med J (Engl); 2013 Jul; 126(13):2480-4. PubMed ID: 23823821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sclerostin: Another vascular calcification inhibitor?
    Claes KJ; Viaene L; Heye S; Meijers B; d'Haese P; Evenepoel P
    J Clin Endocrinol Metab; 2013 Aug; 98(8):3221-8. PubMed ID: 23788689
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum sclerostin is an independent predictor of mortality in hemodialysis patients.
    Gonçalves FL; Elias RM; dos Reis LM; Graciolli FG; Zampieri FG; Oliveira RB; Jorgetti V; Moysés RM
    BMC Nephrol; 2014 Dec; 15():190. PubMed ID: 25465028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.